The first cholesterol pill of its kind has cleared the Food and Drug Administration: Lipfendra, known generically as enlicitide, from Merck, is a once-daily tablet that blocks PCSK9, a protein that keeps the liver from clearing LDL cholesterol. Until now every drug in that class had to be injected. In two trials of 3,207 adults in total, LDL fell by an average of 56% in one trial and 59% in the other, measured against placebo.
Help yourself and the planet: The Cool Down makes it easy to help yourself while helping the planet, with smart, simple changes to save more and waste less in your everyday life.
We may earn a commission if you sign up.
The approval came in July 2026, and the FDA’s announcement is dated July 17. The agency framed the drug as an add-on to diet and exercise for adults with high cholesterol, including those with an inherited form of the condition. High cholesterol usually causes no symptoms and is often found through routine blood testing, which is why a daily tablet aimed at a number on a lab report matters to so many adults who feel perfectly well.
An oral PCSK9 inhibitor and who it is for
According to the FDA’s announcement, Lipfendra is the first oral inhibitor of proprotein convertase subtilisin/kexin type 9, and it is indicated as an adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. The agency gave the application priority review and also reviewed it under the Commissioner’s National Priority Voucher pilot program, which is meant to speed therapies that address national public health priorities.
Michael Davis, M.D., Ph.D., acting director of the FDA’s Center for Drug Evaluation and Research, said that elevated LDL cholesterol is one of the most important modifiable risk factors for heart disease. In the agency’s words, “This approval provides an additional treatment option for adults with hypercholesterolemia.”
Merck’s announcement specifies a 20 mg tablet taken once a day. Dean Li, president of Merck Research Laboratories, called the approval a pivotal moment for bringing the first FDA-approved oral PCSK9 inhibitor to adults with high LDL cholesterol. Katherine Wilemon, chief executive of the Family Heart Foundation, welcomed it as a new oral option for adults who need additional LDL lowering.
The two trials behind the 56% and 59%
The numbers in the approval come from two randomized, double-blind, placebo-controlled trials that together enrolled 3,207 adults on maximally tolerated statin therapy. The primary endpoint was the percent change in LDL cholesterol from baseline to week 24 compared with placebo. In the first trial, which enrolled adults with established or high-risk atherosclerotic cardiovascular disease and a mean baseline LDL of 96 mg/dL, Lipfendra lowered LDL by an average of 56% versus placebo. In the second trial, in adults with heterozygous familial hypercholesterolemia and a mean baseline of 119 mg/dL, the average reduction was 59%.
Merck identifies the studies as CORALreef Lipids, registered as NCT05952856, which randomized 2,904 patients two to one to Lipfendra or placebo for 52 weeks, and CORALreef HeFH, registered as NCT05952869, which randomized 303 patients, 202 to Lipfendra and 101 to placebo. Those two enrollments add up to the 3,207 adults in the FDA’s description. The two percentages are separate results from separate populations, not a single pooled figure.
Measured from each patient’s own baseline rather than against placebo, Merck reported that LDL fell 57% in the Lipids trial while rising 3% on placebo, and fell 58% in the familial hypercholesterolemia trial against a 3% rise on placebo. Non-HDL cholesterol dropped 54% and 52% in the two trials, and apolipoprotein B fell 50% and 48%.
Side effects, open questions and access
On safety, the FDA reported that adverse reaction frequency in the first trial was similar between Lipfendra and placebo. In the second trial, the reactions that occurred more often with the drug were diarrhea and dizziness, which Merck put at 7% versus 2% for diarrhea and 9% versus 4% for dizziness. The FDA’s background explains that excess LDL can build up in artery walls and form plaques that narrow vessels, and that a ruptured plaque can trigger a clot that raises the risk of heart attack or stroke. Across both trials the share of patients who stopped treatment because of adverse reactions was comparable between the drug and placebo groups.
What the trials measured is cholesterol, not heart attacks or strokes. Reporting by TCTMD notes that the CORALreef Outcomes trial has finished enrolling more than 14,500 participants, and Merck states that it is not yet known whether Lipfendra lowers cardiovascular morbidity or mortality. Jeffrey Berger of NYU Langone told TCTMD that some patients may be hesitant to take an injectable medication, but that clinicians are still waiting for outcomes data showing fewer heart attacks and strokes.
Berger also said access will depend on pricing, insurance coverage and how payers fit the drug into treatment pathways, and neither the FDA nor Merck’s announcement gave a price. He stressed that the pill adds to existing options, which include statins, ezetimibe and the injectable PCSK9 inhibitors such as evolocumab and alirocumab, rather than replacing them. More background on the approval is in the FDA’s drug announcement.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
Help yourself and the planet: Get The Cool Down →
We may earn a commission if you sign up.
More from Morning Overview
